P/E ratio for Novavax (NVAX)
P/E ratio as of April 2024 (TTM): -0.5494
According to Novavax's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.549374. At the end of 2022 the company had a P/E ratio of -1.24.
P/E ratio history for Novavax from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.24 | -79.84% |
| 2021 | -6.14 | -62.59% |
| 2020 | -16.4 | 2239.61% |
| 2019 | -0.7019 | -80.73% |
| 2018 | -3.64 | 85.12% |
| 2017 | -1.97 | 60.9% |
| 2016 | -1.22 | -91.4% |
| 2015 | -14.2 | -13.67% |
| 2014 | -16.5 | -0.27% |
| 2013 | -16.5 | 92.25% |
| 2012 | -8.59 | 15.91% |
| 2011 | -7.41 | 3.7% |
| 2010 | -7.15 | 26.28% |
| 2009 | -5.66 | 58.71% |
| 2008 | -3.57 | -38.96% |
| 2007 | -5.84 | -44.43% |
| 2006 | -10.5 | -29% |
| 2005 | -14.8 | 222.5% |
| 2004 | -4.59 | -54.85% |
| 2003 | -10.2 | 259.84% |
| 2002 | -2.83 | -91.38% |
| 2001 | -32.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.5 | -4,921.23% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.6 | -2,572.01% | 🇺🇸 USA |
 AstraZeneca AZN | 37.8 | -6,980.29% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 11.7 | -2,227.18% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | -16.3 | 2,861.46% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -15.1 | 2,650.09% | 🇺🇸 USA |
 Agenus
AGEN | -9.76 | 1,677.42% | 🇺🇸 USA |
 NanoViricides NNVC | -1.88 | 242.46% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | -3.33 | 505.78% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -0.1614 | -70.62% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.